Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:01 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Use of Tranexamic Acid in Reduction of Post-Op Complications in Mohs Micrographic Surgery
NCT04630886 · Riley McLean · EARLY_PHASE1 · terminated · last registry update 2024-11-19 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Drug supply issues” | – | Registry record, Riley McLean |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PLG within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-10-31Results posted on the registry: Nicoletta C Machin, Recombinant Von Willebrand factor + Tranexamic Acid Injection [Cyklokapron] (NCT04344860)
- 2025-10-28Results posted on the registry: NHS Blood and Transplant, Tranexamic acid (TXA). + Placebo (NCT03136445)
- 2025-10-08Phase 3 first posted: University of Health Sciences Lahore, Tranexamic Acid (TXA) (NCT07212452)
- 2025-09-29Results posted on the registry: University of California, San Francisco, Tranexamic Acid (NCT05807074)
- 2025-09-29Also stopped (terminated): University of California, San Francisco, Tranexamic Acid (NCT05807074)
- 2025-08-15Phase 3 first posted: Louisiana State University Health Sciences Center in New Orleans, Tranexamic Acid (TXA) treatment + Placebo (NCT07125508)
- 2025-07-22Also stopped (terminated): Istituto Ortopedico Rizzoli, Tibial osteotomy with Tranexamic acid (NCT04785651)
- 2025-06-05Phase 3 first posted: Beijing Anzhen Hospital, Autologous Platelet Rich Plasma (NCT07005661)
- 2025-05-21Results posted on the registry: University of Kansas Medical Center, Tranexamic Acid (TXA) (NCT04347122)
- 2025-05-21Also stopped (terminated): University of Kansas Medical Center, Tranexamic Acid (TXA) (NCT04347122)
- 2025-05-20Also stopped (terminated): North York General Hospital, a drug against PLG (NCT05490186)
- 2025-05-02Also stopped (withdrawn): University of Florida, Tranexamic acid (NCT06644079)
- 2025-04-14Also stopped (withdrawn): University Hospital, Basel, Switzerland, ferric carboxymaltose + tranexamic acid (NCT04625530)
- 2025-03-30Phase 3 first posted: University of Alabama at Birmingham, oral tranexamic acid + Placebo (NCT06902714)
- 2025-03-25Results posted on the registry: George Washington University, Tranexamic Acid (NCT03287336)
- 2025-02-21Also stopped (withdrawn): Northwestern University, Tranexamic acid + Normal saline (NCT05554211)
- 2025-01-31Also stopped (withdrawn): The University of Texas Medical Branch, Galveston, Tranexamic acid + Vasopressin (NCT06419075)
- 2024-12-20Also stopped (terminated): St. Jude Children's Research Hospital, Tranexamic Acid (NCT04410042)
- 2024-12-13Also stopped (withdrawn): Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute), Tranexamic acid (TXA) (NCT05802238)
- 2024-12-05Results posted on the registry: St. Jude Children's Research Hospital, Tranexamic Acid (NCT04410042)
- 2024-11-27Phase 3 first posted: District Headquarters Teaching Hospital Sahiwal, Tranexamic Acid + Calcium dobesilate (Doxium) (NCT06707051)
- 2024-11-21Results posted on the registry: University of Missouri-Columbia, Tranexamic acid + normal saline (NCT04541303)
- 2024-10-22Results posted on the registry: Wake Forest University Health Sciences, Tranexamic acid + Epsilon Aminocaproic Acid (NCT02656472)
- 2024-10-21Also stopped (terminated): University of Nove de Julho, a drug against PLG (NCT05326997)
- 2024-10-15Also stopped (withdrawn): University of Kansas Medical Center, Tranexamic Acid + Normal Saline (NCT06638749)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision